Head and Neck Cancer

Continuous Infusion of Paclitaxel Well Tolerated With Radiation

Published in Cancer Weekly, May 8th, 2001

by N.R. Saltmarsh, staff medical writer - Patients with locally advanced squamous cell cancer of the head and neck (SCCHN) are able to tolerate concurrent radiation therapy and paclitaxel infusion, according to a U.S. National Cancer Institute Phase I trial.

D.I. Rosenthal and colleagues enrolled 27 patients with untreated stage IVA/B SCCHN to receive a seven-week continuous infusion of paclitaxel along with 70 Gy of radiation therapy for seven weeks.

"The dose-response relationship for paclitaxel may depend more on exposure duration than on peak concentration," proposed Rosenthal and team, noting that paclitaxel is an in vitro...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-05-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry